Question

In: Accounting

Grossman Products began operations in 2018. The following selected transactions occurred from September 2018 through March...

Grossman Products began operations in 2018. The following selected transactions occurred from September 2018 through March 2019. Grossman's fiscal year ends on December 31.

2018:

(a.) On September 5, Grossman opened a checking account and negotiated a short-term line of credit of up to $10,500,000 at 10% interest. The company is not required to pay any commitment fees.

(b.) On October 1, Grossman borrowed $8,500,000 cash and issued a 5-month promissory note with 8% interest payable at maturity.

(c.) Grossman received $3,500 of refundable deposits in December for reusable containers.

(d.) For the September through December period, sales totaled $5,500,000. The state sales tax rate is 4% and 80% of sales are subject to sales tax.

(e.) Grossman recorded accrued interest.


2019:

(f.) Grossman paid the promissory note on the March 1 due date.

(g.) Half of the storage containers are returned in March, with the other half expected to be returned over the next 6 months.


Required:
1. Prepare the appropriate journal entries for the 2018 transactions.
2. Prepare the liability section of the balance sheet at December 31, 2018, based on the data supplied.
3. Prepare the appropriate journal entries for the 2019 transactions.

Solutions

Expert Solution

Answer-1.
Journal Entry
S. No. Particulars Dr. Amt. Cr. Amt.
a No Entry
b Cash          8,500,000
Notes Payable          8,500,000
(record the issue of note)
c Cash                  3,500
Liability - Refundable Deposits                  3,500
(record the deposits received against reusable containers)
d. Accounts Receivable          5,676,000 $5,500,000 + $176,000
Sales Revenue          5,500,000
Sales Tax Payable              176,000 $5,500,000 X 4% x 80%
(Record the sales fron sep to dec)
e. Interest Expenses              170,000 $8,500,000 X 8% X 3/12
Interest Payable              170,000
(record the interest due on note)
Answer 2.
Balance Sheet (Partial)
As on Dec 31, 2018
Liabilities
Current Liabilities
Liability - Refundable Deposits                  3,500
Sales Tax Payable              176,000
Interest Payable              170,000
Notes Payable          8,500,000
Total Current Liabilities          8,849,500
Answer 3.
Journal Entry
S. No. Particulars Dr. Amt. Cr. Amt.
f. Interest Expenses              113,333 $8,500,000 X 8% X 2/12
Interest Payable              170,000
Notes Payable          8,500,000
Cash          8,783,333
(record the note paid)
g. Liability - Refundable Deposits                  1,750 $3,500 / 2
Cash                  1,750
(Record the deposit returned for containers)

Related Solutions

Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $15,000,000 at the bank's prime rate (10.5% at the time). The company will pay no commitment fees. On October 1, borrowed $12...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $23,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $20...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $8,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $5...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $16...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $16...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2018. The following selected transactions relate to liabilities of the company for September 2018 through March 2019. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2018 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $19,000,000 at the bank’s prime rate (12.5% at the time). The company will pay no commitment fees. On October 1, borrowed $16...
Camden Biotechnology began operations in September 2016. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2016. The following selected transactions relate to liabilities of the company for September 2016 through March 2017. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2016 a. On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $29,000,000 at the bank’s prime rate (9.5% at the time). The company will pay no commitment fees. b. On October 1,...
Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the...
Camden Biotechnology began operations in September 2021. The following selected transactions relate to liabilities of the company for September 2021 through March 2022. Camden’s fiscal year ends on December 31. Its financial statements are issued in April. 2021 On September 5, opened checking accounts at Second Commercial Bank and negotiated a short-term line of credit of up to $25,000,000 at the bank's prime rate (9.5% at the time). The company will pay no commitment fees. On October 1, borrowed $22...
Tony Corporation began operations on January 1, 2018. The following transactions relating to stockholders’ equity occurred...
Tony Corporation began operations on January 1, 2018. The following transactions relating to stockholders’ equity occurred in the first two years of the company’s operations. 2018 Jan. 1 Authorized the issuance of 2 million shares of $5 par value common stock and 100,000 shares of $100 par value, 10% cumulative, preferred stock. Jan. 2 Issued 200,000 shares of common stock for $12 cash per share. Jan. 3 Issued 100,000 shares of common stock in exchange for a building valued at...
The following selected transactions relate to contingencies of Eastern Products Inc., which began operations in July...
The following selected transactions relate to contingencies of Eastern Products Inc., which began operations in July 2021. Eastern's fiscal year ends on December 31. Financial statements are published in April 2022. No customer accounts have been shown to be uncollectible as yet, but Eastern estimates that 3% of credit sales will eventually prove uncollectible. Sales were $300 million (all credit) for 2021. Eastern offers a one-year warranty against manufacturer's defects for all its products. Industry experience indicates that warranty costs...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT